Overall Perfomance for "Stock Onion"
The following three charts can be used by potential investors to gauge the performance of "Stock Onion":
107 out of 182 campaigns closed down on first day
65 out of 182 campaigns closed up on first day
10 out of 182 campaigns had no net effect
PSID Promotional Newsletter
The following is a newsletter released by "Stock Onion" promoting PositiveID Corp.
Profits of over 100% aren't hard to come by when
the total upside of this stock is over 3,537%.
Dear Fellow Trader,
One of our most recent Hemp picks has seen some tremendous success. We started showing it to you at $.008 back in Nov and we have seen recent highs of $.048 on Friday Jan 26th representing 464% in Gains from my alert.
Where else are you seeing gains like that
It's time for you to grab hold to another potential 100%, 200% or even 500% gainer.
Im unleashing what could turn out to be my biggest alert of February and that says a lot considering that just over a week ago my most recent Hemp pick gained 464%...
I've isolated a Tiny Biotech situation with Extensive Patent Portfolio and massive upside potential.
Your Next Step Is To Get Yourself Ready
For Thursdays Blockbuster Biotech Pick PSID
I am Issuing an Immediate Alert on PSID
My New Blockbuster Biotech Pick for Thursday is PSID
Pay close attention because this is the EXACT Catalyst
that could potentially ignite this stock to new levels.
PSID has been making tremendous progress, and has been accomplishing one major milestone after another, with accomplishments like their recent huge news of the Companys successful detection of the influenza virus on its FireflyDX prototype system and its publication of a white paper
PSID could be potentially setting up to be a major player in this billion-dollar sector.
In the United States of America, for example, recent estimates put the cost of influenza epidemics to the economy at US $71-167 billion per year. According to International Journal of Economics Management Sciences.
This year's flu season is already the most widespread on record health officials say, according to an article in the Washington Post.
This years flu season could be the deadliest in years and the most expensive
This flu season is on track to be the worst in nearly a decade. With tens of thousands of patients flocking to hospitals and at least 37 children dead, this years flu season is shaping up to be the worst in nearly a decade and its not over yet.
Early detection is key to preventing the spread of
ordinary seasonal and pandemic flu.
Pandemic influenza is rated among the gravest national risks on the government risk register. Pandemics can occur with unpredictable frequency, infecting populations with a new virus over a relatively short period of time, causing significant illness and mortality and disrupting the function of normal communities. Early detection is key to preventing the spread of ordinary seasonal and pandemic flu. According to Professor Ingemar Cox.
PositiveIDs FireflyDX prototype system has successfully detected influenza virus
The FireflyDX family of products is designed to provide accurate, rapid pathogen detection at the point-of-carepoint-of-need POCPON using real-time PCR in less than 30 minutes, with minimally trained personnel and at a lower cost than existing systems.
Current solutions for accurately identifying potential pathogens and bio-threats, especially at the POCPON, can sometimes take as long as several hours to several days to provide results, dramatically delaying what is often life-saving treatment, while also increasing costs, both personal and financial.
PositiveID and its ExcitePCR subsidiary are developing FireflyDX, in both portable and handheld forms, to enable accurate, fast, safe, cost-effective diagnosis in the field, which may offer a highly disruptive breakthrough in combating influenza, which is often diagnosed with a rapid influenza detection test RIDT. RIDTs are not as accurate, however, as lab-based testing such as PCR. In fact, the CDC recommends that if an important clinical decision is affected by a flu test result, the RIDT result should be confirmed by a molecular assay such as PCR.
According to the CDC, this years flu season is geographically widespread and patients health complications are abnormally high, stated William J. Caragol, Chairman and CEO of PositiveID. Unfortunately, as is often the case, because lab-based testing demands both significant time and financial resources, many people being tested at the point of care or point of need with rapid influenza detection tests are getting results that are only partially accurate, or worse, not accurate at all. This may allow the flu epidemic to worsen. Fast, affordable point-of-need diagnostics should be the first line of defense, and we are developing our technology to offer just such a solution, continued Caragol.
In addition to influenza virus, the FireflyDX prototype system has also successfully detected a number of other pathogenic organisms including Zika, Ebola, E. coli, influenza, MRSA, MSSA, C. diff and others.
PSID has been making tremendous progress, and has been accomplishing one major milestone after another, with accomplishments like their recent huge news that PositiveID's FDA-cleared next generation Caregiver thermometer with Bluetooth capability will be commercially available in January 2018.
Another major milestone accomplishment is PositiveIDs E-N-G Mobile Systems 2017 Bookings Increase 100% Year Over Year. They recently announced that 2017 bookings for its E-N-G Mobile Systems ENG subsidiary increased over 100% from 2016, driven primarily by growth in ENGs mobile labs bookings.
We've been waiting for an undervalued Biotech play with Blockbuster potential and huge upside potential to come along.
We've been waiting patiently for the perfect opportunity for PSID, and it appears the time is now with it at its current level.
A move back to its Sept high of $.04 cents per share, would show traders gains of over 3,537%
PSID looks to be in a great position right now and numerous recent developments could lead to strong upside.
With so much in the pipeline for PSID, a major breakout could be IMMINENT
I strongly suggest you start your research on PSID as I am anticipating this one to run like crazy
I am urging all of our members to add PSID to the top of their watch list right now, and be ready Thursday morning at the opening bell.
Yours for greater profits,
Disclaimer Please Read
Our reportsreleases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never inv.est in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our emailblog list as well as any social networking platforms we may use. LEASE NOTE WELL Neither Our websitenewsletter, its corporate officers, nor any of its affiliates are registered investment advisors or broker dealers, and do not recommend to buy, hold, or sell any securities. Release of Liability Through use of this website viewing or using you agree to hold us, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury monetary or otherwise that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Our websitenewsletter and its employees are not a Regist.ered Inve.stment Adv.isor, Brok.er Dealer or a member of any association for other research providers in any jurisdiction whatsoever. We encourage readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and we make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead we strongly urge you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports Forms 10Q, 10K, Form 8K, insider reports, Forms 3, 4, 5 Schedule 13D. We are compliant with the Can Spam Act of 2003. We do not offer such advice or an analysis, and we further urge you to consult your own independent tax, business, financial and investment advisors. Inve.sting in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Secur.ites Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions quote may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, we have relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable however, such liability cannot be guaranteed. Investors should not rely on the information contained in this website or newsletter. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, we and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. We are not responsible for any claims made by the companies advertised herein, nor are we responsible for any other promotional firm, its program or its structure. This message is meant for informational and educational purposes only and does not provide investment advice. Never make investment decisions based on anything we say. To date we have been compensated Sixty Thousand dollars USD to profile PSID. Please be advised we have been additionally compensated for investor relations and media services for PSID in the amount of Twenty Five Thousand dollars USD by, a non-affiliated third party Silicon Valley Marketing LLC for marketing exposure. We do not own any shares of PSID.
CAUTION IT IS POSSIBLE THAT ALL MONIES MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.